TGFB1 and osteogenesis imperfecta: TGF-β appears as a pathogenic factor and has become a therapeutic target in OI, with favorable effects of its blockade by neutralizing anti-TGF-β antibodies in two mouse models of OI, Crtap−/− and +/G610C mice, with increased bone mass [351].